Topical application of insecticidal recombinant toxin fusion protein
By fusing spider toxin with snowdrop lectin and applying through contact, the problem of poor activity of spider venom peptides during oral administration is solved, effective insecticidal and life cycle interference on pests is achieved, and an efficient biokilling is provided. Method of administration of insecticides.
Patent Information
- Application Number
- CN202380029627.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-06-14
- Filing Date
- 2023-03-23
- Publication Date
- 2024-11-26
AI Technical Summary
The existing spider venom peptides are significantly inactive when taken orally, mainly because they cannot pass through the intestinal epithelium effectively, making it difficult to reach the central nervous system or peripheral nervous system of the insects, and lack of effective oral insecticides.
By fusion with snowdrop lectin (GNA), a recombinant toxin protein is formed, which enhances the oral activity of toxins, and the fusion protein is directly applied to the outer surface of the pest through contact administration. GNA is used to reduce the susceptibility of toxins to intestinal serine proteases. , promote toxins to cross the intestinal epithelium and achieve insecticidal effects.
The oral and contact insecticidal activity of spider toxins is significantly enhanced, effective killing of pests and life cycle interference is achieved, and an alternative route for bioinsecticide application is provided.
Smart Images

Figure CN119031838A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to the development of contact insecticide compositions and their uses. Background Art
[0002] Spider venom is increasingly recognized as a rich and valuable source of neurotoxins that offer the potential for development into novel biopesticides for a growing library of candidate drugs. Most spider venom peptides are short (2.5-5 kDa) and disulfide-rich, and the most distinctive are those containing the evolutionarily conserved inhibitor cystine knot (ICK) motif (Pineda et al., 2020). The ICK motif, defined as an antiparallel β-fold stabilized by a cystine knot (Pallagh et al., 1994), provides a high level of chemical and thermal stability and resistance to proteolytic degradation in the insect gut and hemolymph (Craik et al., 2001; Herzig et al., 2018). Such properties are of great significance for the commercial production and feasibility of biopesticides. In fact, Vestaron registered the Spear TM T, which contains the spider venom neurotoxic peptide GS-ω / κ-hexatoxin (HxTx)-Hv1h (named GS-ω / κ-HxTx-Hv1a by Vestaron) as an active ingredient, provides evidence for the potential for commercialization of venom peptide-based biopesticides.
[0003] GS-ω / κ-HxTx-Hv1h is a member of the ω-HxTx-1 family, one of the first peptides isolated from the venom of the Australian funnel-web spider (Hadronyche versuta) (Atkinson et al., 1996; Fletcher et al., 1997). Well-studied members of a subset of the hexatoxin superfamily (thought to have evolved from a common ancestral gene) also include ω-hexatoxin-Hv1a and hexatoxin-Hv1c. All three toxins have been shown to be effective by injection into a range of insects, but are harmless to mammals and, surprisingly, non-toxic to honey bees (King & Hardy, 2013). ω-hexatoxin-Hv1a was originally shown to target insect voltage-gated calcium channels (Ca2+). v ), while κ-hexatoxin-Hv1c targets calcium-activated potassium channels (K Ca)(Tedford et al., 2004; Chong et al., 2007). Although structurally similar, the mature amino acid sequences of the three toxins differ. GS-ω / κ-HxTx-Hv1h has been designated as a mixed toxin because it contains key amino acid residues present in either ω-hexatoxin-Hv1a or κ-hexatoxin-Hv1c (Chambers et al., 2019). Recently, all three toxins have been shown to act as positive allosteric modulators of the insect nicotinic acetylcholine receptor (nAChR), which mediates the effects of acetylcholine, the major excitatory neurotransmitter in the insect central nervous system (CNS) (Chambers et al., 2019).
[0004] Many venom ICK peptides are highly effective by injection, but are typically significantly less effective when ingested (Saez & Herzig, 2019). Obviously, neurotoxic peptides must enter the CNS or peripheral nervous system (PNS) to reach one or more of their target sites, and the inability of ingested peptides to cross the intestinal epithelium is considered a major obstacle to achieving oral efficacy. Therefore, there is a need to develop new insecticides with enhanced activity, such as by enhancing the delivery of oral insecticides to the CNS and / or PNS of pests or developing improved methods of administration. The inventors have previously demonstrated that a variety of different venom neurotoxins (including ω-hexatoxin-Hv1a) interact with snowdrop lectin (Galanthus The fusion of GNA with a carrier protein (nivalisagglutinin, GNA) significantly enhances oral insecticidal activity (Fitches et al., 2004, 2010, 2012). GNA is able to transport the attached peptide across the insect gut, allowing delivery to the circulatory system. The potential mechanism by which GNA enhances the insecticidal activity of the fusion toxin protein (GNA / Hv1a) may be by reducing the susceptibility of the fusion toxin to intestinal serine proteases (Powell et al., 2019). Similarly, when Hv1a is fused to the yellow dwarf virus coat protein, it passes from the aphid gut to the hemocoel, which has been shown to significantly enhance the oral efficacy of Hv1a against aphids (Bonning et al., 2014). In addition, GNA has been shown to bind to the central nerve cord of lepidopteran larvae, and therefore can also mediate the delivery of attached toxins to sites of action within the CNS (Fitches et al., 2012).
[0005] One of the objects of the present disclosure is to obviate and / or mitigate one or more of the above mentioned disadvantages. Summary of the invention
[0006] The present disclosure is based in part on studies of the contact activity of recombinant GS-ω / κ-HxTx-Hv1h and ω / κ-HxTx-Hv1h / GNA fusion proteins against pea aphids (as a typical example). The results further confirmed that the fusion of recombinant toxins (such as GS-ω / κ-HxTx-Hv1h) with GNA not only enhances oral toxicity, but also importantly enhances the contact efficacy against aphids, i.e., when the toxin is in contact with the outer surface of the aphid and is not ingested. When delivered via the outer surface of the pest by contact application as described herein, the GNA fusion toxin protein of the present disclosure results in unexpectedly enhanced insecticidal activity (relative to the use of toxin protein alone). The enhanced insecticidal performance of the fusion protein is surprising because the role of the carrier protein GNA is to reduce susceptibility to intestinal serine proteases and promote transport across the intestinal epithelium after ingestion (Powell et al., 2019), and would not be expected to have an effect when not administered via the intestine. Similarly, the inventors have surprisingly determined that a peptide containing a structurally similar ICK motif (derived from the sulfur-rich pea albumin PA1) fused to GNA exhibits enhanced contact insecticidal activity.
[0007] In a first aspect, the present disclosure provides a method of controlling insect pests, the method comprising applying to the pests by contact / topical application a pesticide formulation comprising at least one insecticidal recombinant toxin fusion protein.
[0008] Typically, according to particular embodiments of the first aspect, the insect pest is a plant pest or a bee (eg honey bee) pest.
[0009] The term "pest" as used throughout this disclosure includes insects (e.g., ants, cockroaches, mosquitoes), mites, bee pests (e.g., small hive beetles, parasitic mites (Varroa destructor), molluscs (e.g., slugs and snails), and nematodes (e.g., roundworms) that feed on plants (especially crops) and / or trees or parts thereof (such as leaves, sap, flowers, seeds, and / or fruits). Methods of controlling pests (also known as pest management) by contact / topical application include inducing negative effects on adult and / or larval forms of pests by inhibiting growth, impairing movement, impairing reproduction, impairing their metabolic activity, and / or killing. Therefore, the terms "pesticide" or "insecticide" are not intended to refer only to the ability to kill pests, but also include the ability to interfere with the pest life cycle in any way (leading to an overall reduction in the pest population).
[0010] By contact application, the insecticidal recombinant toxin fusion protein can destroy plant pests and bee pests or at least weaken them. Examples of plant and bee pests include, but are not limited to, thrips (Thysanoptera), whiteflies (Aleyrodidae), aphids (Aphidoidea), plant lice (Psyllidae), beetles (Coleoptera), spider mites (Tetranychidae), broad mites (Tarsonemidae), plant lice (Delphacidae), flies (Diptera), moths (Lepidoptera) or their larvae, cockroaches (Blattodea) or ants (Formicidae). In one embodiment, the insecticidal recombinant toxin fusion protein as described herein is used to control aphids, wood lice, thrips, whiteflies, mites and / or their larvae by contact application.
[0011] The insecticide formulation delivered by contact application as described herein comprises one or more recombinant toxin fusion proteins. In one embodiment, the insecticidal recombinant toxin fusion protein comprises a neurotoxin, which can be selected from a toxin derived from arachnids or a toxin derived from an insect. In one embodiment, the toxin derived from arachnids can be a spider toxin, which typically acts as a neurotoxin. Examples of such neurotoxins include, but are not limited to, hexatoxins (κ-, δ- or ω-hexatoxins (HxTx)), ω-atracotoxin, δ-atracotoxin (also referred to as δ-ACTX-Ar1, robustoxin or robustotoxins), Cupiennius salei toxins, and spider potassium channel inhibitory toxins (e.g., hanatoxin, heteropodatoxin). Other examples of peptide venom toxins may include those derived from Hymenoptera (e.g., poneratoxin from bullet ants (Paraponera clavate)), threonine (6)-bradykinin from the venom of social wasps such as Polybia accidentalis).
[0012] In one embodiment, the toxin of one or more insecticidal recombinant fusion proteins of the present disclosure is selected from hexatoxin. For example, Hadrncyhe versuta produces toxins ω-hexatoxin-Hv1e, ω-hexatoxin-Hv1c, ω-hexatoxin-Hv1d, ω-hexatoxin-Hv1g, and ω-hexatoxin-Hv1b, each of which has a very high level of sequence identity (only a few amino acid substitutions or deletions between the various toxins). The Sydney funnel-web spider (Atrax robustus) produces toxin proteins ω-hexatoxin-Ar1d (which has the same amino acid sequence as ω-atracotoxin-Hv1a), as well as ω-hexatoxin-Hv1h and ω-hexatoxin-Ar1f (which have a very high level of sequence identity). In addition, toxins are also produced by the short-chested long-haired spider Tibellus oblongus (ω-Tbo-IT1 toxin), the Toowoomba funnel-web spider Hadronyche infensa (e.g., ω-hexatoxin-Hilb, ω-hexatoxin-Hild, ω-hexatoxin-Hile, ω-hexatoxin-Hilf) and the Tasmanian funnel-web spider Hadronyche venenata (e.g., hexatoxin-Hvn1b, hexatoxin-Hvn1b), and the northern arboreal funnel-web spider Hadronyche formidabilis (hexatoxin-Hf1a). In addition, toxins are also produced by arachnids, such as AaHIT from Androctonus australis and OdTx12 from Odontobuthus doniae.
[0013] Exemplary hexatoxins used herein can be selected from the following identified sequences:
[0014] ω-hexatoxin-Hv1a (SEQ ID NO: 1)
[0015] SPTCIPSGQPCPYNENCCSQSCTFKENENGNTVKRCD
[0016] GS-ω / κ-HxTx-Hv1h(SEQ ID NO:2)
[0017] GSQYCVPVDQPCSLNTQPCCDDATCTQERNENGHTVYYCRA
[0018] ω-hexatoxin-Hv1g (SEQ ID NO: 3)
[0019] QYCVPVDQPCSLNTQPCCDDATCTQELNENDNTVYYCRA
[0020] Peptides containing the ICK motif (referred to herein as ICK peptides) are evolutionarily conserved between phyla. ICK peptides are particularly abundant in cone snail and spider venoms and are known to inhibit voltage-gated ion channels (Fletcher et al., 1997). ICK peptides or ICK proteins contain a structural motif containing three disulfide bonds, wherein the ICK motif is defined as an antiparallel β-fold stabilized by a cystine knot. As used herein, ICK peptides or ICK proteins or ICK toxins refer to peptides, proteins or toxins containing one or more ICK motifs. It is contemplated that toxins containing one or more ICK motifs (which are not necessarily derived from insects or arachnids) may also be effectively used as insecticidal recombinant toxin fusion proteins for contact / topical application as disclosed herein. For example, a sulfur-rich pea albumin (referred to as PA1) in pea (Pisum sativum) seeds is expressed as a preprotein in seeds, which is cleaved into its mature proteins PA1a and PA1b. PA1b is a 37 amino acid peptide containing 6 cysteine residues forming 3 intramolecular disulfide bonds and is an ICK peptide. PA1b is structurally similar to the ICK atracotoxin present in the venom of the Australian funnel-web spider Hadronyche infensa, which can be used as an insecticidal toxin. Therefore, a recombinant fusion protein comprising a peptide derived from pea albumin is used herein as an exemplary non-arachnoid-derived toxin.
[0021] An exemplary pea albumin used herein comprises the following sequence:
[0022] Pea albumin (PAF) (SEQ ID NO: 14)
[0023] EAEAAAASCNGVCSPFEMPPCGSSACRCIPVGLLIGYCRNPSGVFLKGNDEHPNLCESDADCKKKGSGNFCGHYPNPDIEYGWCFASKSEAEDVFSKITPKDLLKSVSTAVDHHHHHHH
[0024] In one embodiment, the insecticidal recombinant toxin fusion protein for contact application as described herein includes a protein or peptide containing an ICK motif, wherein the protein or peptide containing the ICK motif comprises one or more ICK motifs. In one embodiment, the insecticidal recombinant toxin fusion protein for contact application as described herein includes a protein or peptide containing an ICK motif, or a fragment or variant thereof.
[0025] In one embodiment, the insecticidal recombinant toxin fusion protein for contact application as described herein comprises pea albumin derived from pea (Pisum sativum) seeds. In a preferred embodiment, the insecticidal recombinant toxin fusion protein for contact application comprises PA1a or PA1b, or a fragment or variant thereof.
[0026] Recombinant toxin proteins (and variants or fragments thereof) as disclosed herein are fused with another peptide or protein to form an insecticidal fusion protein. Typically, fusion proteins can be produced by expressing a translation coupling sequence encoding a recombinant toxin protein (and variants or fragments thereof) as disclosed herein together with another protein or peptide. Another protein or peptide can be directly connected to the nucleic acid encoding the recombinant protein in frame, so that another protein / peptide is directly fused to, for example, the N-terminus or C-terminus of the recombinant toxin. Alternatively, a linker sequence can be provided so that there is a gap between the recombinant toxin and another protein / peptide. For example, the use of such a linker can promote the folding of the fusion protein. Exemplary linker sequences include (G)nS(A)n(SEQ ID NO:4), (G)n(SEQ ID NO:16), (GGGGS)n(SEQ ID NO:5) (wherein n is 2-6), GGGGSAAA(SEQ ID NO:17), GGGGGGGGSAAAAAA(SEQ ID NO:18) and GSSGSSAAAAAA(SEQ ID NO:19).
[0027] The toxin part of the insecticidal recombinant fusion protein can be a full-length wild-type toxin protein, or can include a variant or fragment thereof. The "variant" or "fragment" of the recombinant toxin protein of the present disclosure can include an amino acid sequence of a toxin protein different from the wild-type sequence, provided that the variant or fragment substantially retains at least 50%, 60%, 70%, 80%, 90% or 95% of the biological activity of the wild-type sequence. In particular, a single like-for-like change in the physicochemical properties of the corresponding wild-type amino acid may not interfere with functionality, and in addition small deletions or insertions in the non-functional regions of the protein toxin can also be tolerated, and are therefore considered to be "variants" for the purposes of the present invention. Technicians can easily use the experimental procedures described herein to determine whether a "variant" or "fragment" still has sufficient biological activity. "Variants" may also include recombinant toxin proteins or fragments with additional affinity tags for purification (such as His-tags, FLAG-tags, HA-tags or Myc-tags) and / or tags that promote expression (such as the dipeptide GS attached to the N-terminus of the toxin. "Fragment" refers to when a portion of the N-terminus and / or C-terminus has been deleted. For example, in one embodiment, a fragment of a toxin protein is a peptide that contains at least 80%, 90% or 95% of the full-length wild-type toxin.
[0028] The length of toxin fusion proteins as described herein is typically less than 300, 200 or 150 amino acids. Variants or fragments of toxin proteins can differ from naturally occurring proteins in length and / or in sequence, e.g., differ by a maximum of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 amino acid residues.
[0029] In one embodiment, the insecticidal toxin protein (and its variant or fragment) can be fused with a carbohydrate binding module (CBM). As known in the art, CBM is a protein module found in glycoside hydrolases that bind polysaccharides. CBM is defined as a continuous amino acid sequence with discrete folds in a carbohydrate-active enzyme (with carbohydrate binding activity). The length range of the CBM protein module can be 40 to 150 amino acids. More than 85 different CBM families have been identified in the CAZy (Carbohydrate Active Enzyme) database. The carbohydrate binding module can be derived from various organisms, such as plants and microorganisms (e.g., bacteria, fungi). In one embodiment, the toxin protein can be fused to the N-terminus or C-terminus of the CBM. In one embodiment, the toxin protein is bound to the N-terminus of the CBM.
[0030] In one embodiment, toxin protein can be fused with lectin. As used herein, the term lectin refers to any molecule (including natural or genetically modified proteins) that specifically interacts with sugars (e.g., carbohydrates). As used herein, the term lectin can also refer to lectins derived from any species (including but not limited to plants, animals, insects, and microorganisms) with the desired carbohydrate binding specificity. Examples of plant lectins include but are not limited to the Leguminosae lectin family, such as Concanavalin A, soybean lectin, peanut lectin, lentil lectin, and the Galanthus nivalisagglutinin (GNA) (GNA is also referred to as the Galanthus nivalisagglutinin) from the Galanthus (Galanthus) (snowdrop) plant. Other examples of plant lectins are Gramineae and Solanaceae lectin families. Examples of animal lectins include but are not limited to any known lectin in the main group S-type lectin, P-type lectin, I-type lectin, C-type lectin, and mannose binding lectin.
[0031] Other exemplary lectins that can be fused to the insecticidal recombinant toxin protein are collectins. Collectins are soluble pattern recognition receptors belonging to the collagen superfamily containing C-type lectins. Additional exemplary lectins include, but are not limited to, mannose binding lectin (also known as mannan binding lectin, mannan binding protein or mannose binding protein), surfactant protein D, liver collectin 1, placental collectin 1, conglutinin, 43kDa lectin, 46kDa lectin or variants thereof. In one embodiment, the CBM of the recombinant toxin fusion protein can be a mannose binding lectin. Exemplary mannose binding lectins include ginger (Zingiberofficinale) mannose binding lectin and garlic (Allium sativum) mannose binding lectin. In a certain embodiment, the lectin includes GNA or a variant thereof.
[0032] In one embodiment, the fusion protein may comprise or consist of a toxin (such as ICK toxin or a peptide containing an ICK motif) (as well as variants or fragments thereof) fused to GNA.
[0033] In some embodiments, the fusion protein may include or consist of a pea albumin-derived toxin (and variants or fragments thereof) fused to GNA. In some embodiments, the fusion protein may include or consist of PAF fused to GNA.
[0034] In one embodiment, the fusion protein may comprise or consist of a toxin such as a spider toxin (as well as variants or fragments thereof) fused to GNA.
[0035] In certain embodiments, the fusion protein may include or consist of hexatoxin (as well as variants or fragments thereof) fused to GNA.
[0036] In an alternative embodiment, the fusion protein may comprise or consist of HxTx-Hv1h fused to GNA.
[0037] In one embodiment, the fusion protein may comprise or consist of GS-ω / κ-HxTx-Hv1h fused to GNA.
[0038] Exemplary toxin-GNA fusion sequences are provided below:
[0039] 1.GS-ω / κ-HxTx-Hv1h / GNA(SEQ ID NO:6)
[0040] GSQYCVPVDQPCSLNTQPCCDDATCTQERNENGHTVYYCRAGGGGSAAADNILYSGETLSTGEFLNYGSFVFIMQEDCNLVLYDVDKPIWATNTGGLSRSCFLSMQTDGNLVVYNPSNKPIWASNTGGQNGNYVCILQKDRNVVIYGTDRWATGVDHHHHHH
[0041] 2. GNA / GS-ω / κ-HxTx-Hv1h (SEQ ID NO:7)
[0042] HHHHHHDNILYSGETLSTGEFLNYGSFVFIMQEDCNLVLYDVDKPIWATNTGGLSRSCFLSMQTDGNLVVYNPSNKPIWASNTGGQNGNYVCILQKDRNVVIYGTDRWATGGGGSAAAGSQYCVPVDQPCSLNTQPCCDDATCTQERNENGHTVYYCRA
[0043] 3. ω-Conotoxin-Hv1a / GNA (SEQ ID NO:8)
[0044] SPTCIPSGQPCPYNENCCSQSCTFKENENGNTVKRCDAAADNILYSGETLSTGEFLNYGSFVFIMQEDCNLVLYDVDKPIWATNTGGLSRSCFLSMQTDGNLVVYNPSNKPIWASNTGGQNGNYVCILQKDRNVVIYGTDRWATGVDHHHHHH
[0045] 4. ω-Conotoxin-Hv1a (K-Q mutation) / GNA (SEQ ID NO:9)
[0046] ASPTCIPSGQPCPYNENCCSQSCTFKENENGNTVQRCDAAADNILYSGETLSTGEFLNYGSFVFIMQEDCNLVLYDVDKPIWATNTGGLSRSCFLSMQTDGNLVVYNPSNKPIWASNTGGQNGNYVCILQKDRNVVIYGTDRWATG
[0047] 5. pro-ω-Conotoxin-Hv1a / GNA (SEQ ID NO:10)
[0048] Note: "ω-Conotoxin" is also known as "ω-六毒素" in Chinese. Here, it is translated according to the common English name in the field of biology. Also, "GNA" is left as it is without further translation as it might be a specific abbreviation or name in a particular context.TRADLQGGEAAEKVFRRSPTCIPSGQPCPYNENCCSQSCTFKENENGNTVKRCDAAADNILYSGETLSTGEFLNYGSFVFIMQEDCNLVLYDVDKPIWATNTGGLSRSCFLSMQTDGNLVVYNPSNKPIWASNTGGQNGNYVCILQKDRNVVIYGTDRWATGVDHHHHHH
[0049] 6. Pro-ω-conotoxin-Hv1a (K-Q mutation) / GNA (SEQ ID NO:11)
[0050] TRADLQGGEAAEKVFRRSPTCIPSGQPCPYNENCCSQSCTFKENENGNTVQRCDAAADNILYSGETLSTGEFLNYGSFVFIMQEDCNLVLYDVDKPIWATNTGGLSRSCFLSMQTDGNLVVYNPSNKPIWASNTGGQNGNYVCILQKDRNVVIYGTDRWATGVDHHHHHH
[0051] 7. GNA / ω-conotoxin-Hv1a / His (SEQ ID NO:12)
[0052] DNILYSGETLSTGEFLNYGSFVFIMQEDCNLVLYDVDKPIWATNTGGLSRSCFLSMQTDGNLVVYNPSNKPIWASNTGGQNGNYVCILQKDRNVVIYGTDRWATGAAASPTCIPSGQPCPYNENCCSQSCTFKENENGNTVKRCDVDHHHHHH
[0053] 8. His / GNA / ω-conotoxin-Hv1a (k-Q mutation) (SEQ ID NO:13)
[0054] AAAHHHHHHDNILYSGETLSTGEFLNYGSFVFIMQEDCNLVLYDVDKPIWATNTGGLSRSCFLSMQTDGNLVVYNPSNKPIWASNTGGQNGNYVCILQKDRNVVIYGTDRWATGAAASPTCIPSGQPCPYNENCCSQSCTFKENENGNTVQRCD
[0055] 9. PAF / GNA / His fusion protein sequence (SEQ ID NO:15)
[0056] EAEAAAASCNGVCSPFEMPPCGSSACRCIPVGLLIGYCRNPSGVFLKGNDEHPNLCESDADCKKKGSGNFCGHYPNPDIEYGWCFASKSEAEDVFSKITPKDLLKSVSTAAAA DNILYSGETLSTGEFLNYGSFVFIMQEDCNLVLYDVDKPIWATNTGGLSRSCFLSMQTDGNLVVYNPSNKPIWASNTGGQNGNYVCILQKDRNVVIYGTDRWATGVDHHHHHHH
[0057] The present disclosure is based on contact application to pests. According to the present disclosure, but not wishing to be bound by theory, it is believed that the insecticidal recombinant toxin fusion protein can be absorbed by the outer surface area (exoskeleton or integument) of the pest and / or transferred via the respiratory openings called spiracles. Therefore, the recombinant toxin fusion protein as described herein is delivered to the pest by contact application.
[0058] Contact application (or also referred to as topical application) comprises applying the insecticidal recombinant toxin fusion protein so that the recombinant toxin fusion protein contacts at least a portion of the exoskeleton / cuticle of the pest. Contact application may mean applying the insecticide composition directly to the pest. In another case, contact application may refer to indirect or secondary application, in which the insecticide is locally transferred to the pest or larvae by contact with an insecticide-treated surface. For the avoidance of doubt, although the insecticide may be ingested by the pest during topical application, the present disclosure is based on the surprising discovery that recombinant toxins can induce enhanced toxic effects by contact with the exoskeleton / cuticle of the pest compared to the toxin alone.
[0059] The method of contact application can include applying the insecticidal recombinant toxin fusion protein to the environment of the pest, such as by spraying, applying in the form of a dense fog or mist, painting or brushing on a surface, or by other similar methods that may expose the pest to the insecticidal toxin fusion protein. Other exemplary methods include applying droplets of the insecticidal recombinant protein in a solution or using an atomizer to disperse the insecticidal toxin to contact the pest.
[0060] The insecticidal recombinant fusion protein is administered in the form of an insecticide formulation. The insecticide formulation comprises an insecticidal recombinant toxin protein formulated with one or more acceptable excipients, carriers and / or adjuvants. In one embodiment, the adjuvant may be an oil and / or emulsifying surfactant formulated for agricultural applications of the insecticide. In a certain embodiment, the insecticidal formulation comprises a nonionic diffusion and penetration surfactant (e.g., polysorbate 20, Break- ). Commercial formulations typically have oils and / or emulsifying surfactants to facilitate dispersion of the active ingredient, such as methylated or ethylated vegetable oils. In some examples, the insecticidal recombinant fusion protein formulation can be an aqueous solution containing one or more nonionic silicone surfactants (e.g., Silwet, CapSil) with enhanced wetting and spreading properties.
[0061] Insecticidal formulations can be applied alone or in combination with other compounds / formulations (including but not limited to other insecticides). They can be used in combination with other excipients (such as surfactants, detergents, polymers). Insecticidal formulations can also be in the form of slow-release formulations, in which the insecticidal toxin fusion protein is released over a period of time (such as within a few hours, for example 2-12 hours). Insecticidal formulations can also contain one or more pest attractants, such as pheromones, plant volatiles, flower oils, sugars, proteins and / or other molecules known in the art to act as pest attractants.
[0062] In one embodiment, the insecticide recombinant toxin fusion protein can be formulated in combination with an excipient intended to promote adhesion to the outer surface of the pest. For example, the excipient can include a viscous solution of a sugar solution or any other substance that enhances the binding of the insecticide recombinant protein to the outer surface or cuticle (upper cuticle, outer cuticle, inner cuticle and / or cuticle) of the pest.
[0063] In one embodiment, there is provided a pesticide formulation as described herein, formulated as a viscous solution for promoting attachment to the outer surface or cuticle (epidermis, outer cuticle, inner cuticle and / or cuticle) of a pest and subsequent absorption through the outer surface or cuticle.
[0064] In one embodiment, there is provided a use of a pesticide formulation as described herein in a method for controlling pests, wherein the pesticide formulation is applied by contacting the pests.
[0065] Recombinant toxin fusion proteins as described herein can be provided by methods for preparing nucleic acid molecules encoding recombinant toxins / fusion proteins (and variants or fragments thereof) via conventional molecular biology techniques known in the art. The term recombinant fusion protein as used herein also includes the possibility that fusion proteins can be prepared by de novo chemical synthesis techniques known in the art. A variety of methods have been developed to connect polynucleotides to form continuous single or double strands, especially double-stranded DNA, such as by complementary sticky ends produced by digestion with restriction enzymes. Suitable methods are described in Sambrook et al. (2000) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Technicians can easily use such methods to prepare nucleic acid molecules according to the present disclosure.
[0066] In one embodiment, the nucleic acid encoding the recombinant toxin fusion protein is provided in an expression construct. "Expression construct" is a term well known in the art. Expression constructs are basic tools for producing recombinant proteins in biotechnology. The term "construct" refers to a non-naturally occurring nucleic acid molecule. Constructs can refer to polynucleotides encoding fusion polypeptides. Constructs can also include circular or linear vectors, and can be combined with other polynucleotides, such as by homologous recombination. The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop into which additional DNA segments can be connected. Another type of vector is a viral vector, in which additional DNA segments can be connected to the viral genome. Certain vectors are capable of autonomous replication in the host cell into which they are introduced (e.g., bacterial vectors and additional mammalian vectors with bacterial replication start points). Other vectors (e.g., non-additional mammalian vectors) are integrated into the genome of the host cell after being introduced into the host cell, and are thereby replicated together with the host genome. The vector of the present invention can direct the expression of a gene encoding a target polypeptide operably connected thereto. Such a vector is referred to herein as an "expression vector". Generally speaking, expression vectors useful in recombinant DNA techniques are usually in the form of plasmids. In this specification, "plasmid" and "vector" can be used interchangeably, as plasmids are the most commonly used form of vectors.
[0067] Expression constructs generally include plasmids for introducing the desired coding sequence and appropriate nucleic acid sequences required for expressing the operably connected coding sequence in a specific host cell. The nucleic acid sequence required for expression in prokaryotes includes a promoter, an optional operator sequence, a ribosome bind site, and possible other sequences. Known eukaryotic cells utilize promoters, enhancers, and termination signals and polyadenylation signals. The secretion signal peptide sequence may also be optionally encoded by a recombinant expression vector, operably connected to a coding sequence for a recombinant protein (such as a recombinant fusion protein) so that the expressed fusion protein can be secreted by the recombinant host cell, so that the fusion protein can be more easily separated from the cell (if desired). The term includes a carrier as an autonomously replicating nucleic acid structure and a carrier that is integrated into the genome of the host cell into which it has been introduced.
[0068] Can select or construct and comprise the suitable expression construct for being introduced into the nucleic acid in microorganism and higher organism, it contains suitable regulating sequence, and this comprises promoter sequence, terminator fragment, enhancer sequence, marker gene and other suitable sequences.For more detailed information, referring to for example Molecular Cloning:a Laboratory Manual:2nd edition (molecular cloning: laboratory manual: second edition, people such as Sambrook, above.The nucleic acid for expressing in suitable host organism can also be carried out codon optimized for the expression in selected host, and this is well-known to technicians.
[0069] Once the expression construct is inside the cell, the protein encoded by the gene is produced by the cellular transcription and translation machinery ribosomal complex. The plasmid also includes the nucleic acid sequences required to maintain and propagate the vector (in some cases by integrating into the host genome). The goal of the expression vector is to produce large amounts of stable messenger RNA, and therefore produce protein.
[0070] Various recombinant expression systems are known in the art, including bacteria, yeast and mammalian host cell systems, and many different proteins have been successfully produced in these systems. Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques known in the art. As used herein, the terms "conversion" and "transfection" are intended to refer to various art-recognized techniques for introducing foreign nucleic acids (such as DNA) into host cells, including calcium phosphate or calcium chloride coprecipitation, DEAE-dextran-mediated transfection, lipofection or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook et al. (MOLECULAR CLONING:A LABORATORY MANUAL.2nd ed. (Molecular cloning: Laboratory Manual, 2nd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) and other laboratory manuals.
[0071] Details
[0072] The present disclosure will now be further described by way of example and with reference to the accompanying drawings, in which is shown:
[0073] Figure 1 .(a) Schematic representation of expression constructs: Schematic representation of constructs encoding recombinant HxTx-Hv1h and HxTx-Hv1h / GNA (produced in the yeast P. pastoris, predicted molecular weights are shown). The tag indicates the presence of a six-residue histidine sequence that allows protein purification by nickel affinity chromatography and detection by western blot. (b) Gel electrophoresis: Purified proteins were separated by SDS-PAGE gel (stained for total protein): lanes 1 and 2 are HxTx-Hv1h, lanes 3 and 4 are HxTx-Hv1h / GNA, lanes 5 and 6 are recombinant GNA, and lane 7 is Sigma GNA standard (2 μg). (c) Immunoblotting: Recombinant proteins were subjected to western blot analysis using anti-His (lanes 1-5 are the same as B) and anti-GNA (lanes 1 and 2 are HxTx-Hv1h / GNA, lane 3 is Sigma GNA standard 50 ng) antibodies. The positions of mass markers run on the same gel are depicted.
[0074] Figure 2Survival of (a) pea aphid (A. pisum) and (b) peach aphid (M. persicae) fed diets containing different concentrations of HxTx-Hv1h, HxTxHv1h / GNA, or GNA. (c) Day 2 LC from bioassay data in (a) and (b). 50 Values (mg / mL). CI depicts confidence intervals, and numbers in parentheses are relative amounts of toxin in fusion protein treatments.
[0075] Figure 3 Survival of (a) pea aphids and (b) peach aphids fed diets containing HxTx-Hv1h, GNA, HxTx-Hv1h / GNA, and an equivalent mixture of HxTx-Hv1h and GNA.
[0076] Figure 4 Composites of whole pea aphids fed a diet containing FITC-labeled protein or control-FITC / PI for 24 h, followed by chase feeding a control diet for 6 h and 24 h. Images were visualized using a fluorescence microscope under a FITC filter and captured in OpenLab (scale bar = 0.5 mm). The lower frame shows adults (fed FITC-fusion protein for 24 h, placed in a feeding chamber overnight) and emerging nymphs.
[0077] Figure 5.(a) Survival of pea aphids 24 h after contact exposure to water, water + Breakthru (BT), different amounts of HxTx-Hv1h (HxTx) or GNA or HxTx-Hv1h / GNA (FP) or a mixture of GNA and toxin. All protein treatments contained Breakthru. The bar graph depicts the standard error of the mean (3 replicates per dose, n=15), and * indicates a significant difference relative to the control (+BT) at *P<0.05, **P<0.01 and ***P<0.0001 (t-test). (b) Pea aphid survival is the same as 5(a), except that aphids were treated with droplets containing equivalent molar concentrations of HxTx or GNA or FP as indicated. As in 5(a), all protein treatments contained Breakthru. Bar graphs depict standard error of the mean (3 replicates per dose, n=15), * indicates significant difference relative to control (+BT) at *P<0.05, **P<0.01, and ***P<0.0001 (t-test). (c) Representative images of aphids taken 18 h after exposure to droplets containing FITC-labeled proteins as follows: 0.31 μg HxTx-Hv1h (HxTx), 0.93 μg GNA, or 1.25 μg HxTx-Hv1h / GNA (FP). Aphids were fed a control diet and washed before imaging under a FITC filter captured in OpenLab. Scale bar = 0.5 mm. (d) Western blot analysis (anti-His antibody) of whole aphid protein extracts extracted 2 h and 18 h after exposure to droplets containing 2.5 μg HxTx-Hv1h, 7.5 μg GNA, and 5 μg fusion protein. S1 depicts the HxTx-Hv1h standard (250 ng), S2 is the recombinant fusion protein (200 ng), and S3 is (100 and 200 ng) recombinant GNA.
[0078] Figure 6.(a) Schematic diagram of expression constructs: Schematic diagram of constructs encoding recombinant Hv1a and His / GNA / Hv1a(kq) and Hv1a / GNA / His (produced in the yeast Pichia pastoris, predicted molecular weights are shown). The tag indicates the presence of a six-residue histidine sequence that allows protein purification by nickel affinity chromatography and detection by Western blotting. (b) SDS-PAGE gel electrophoresis: Purified Hv1a / GNA / His and His / GNA / Hv1a(kq) were separated by SDS-PAGE, and the gel was stained with Coomassie Blue for total protein. The circle of Hv1a / GNA / His depicts the intact fusion protein, and the lower mass cleavage product is GNA (as shown by LC-MS analysis of protein digests); both protein bands of the GNA / Hv1a(kq) band are intact FP (as shown by LC-MS analysis of protein digests).
[0079] Figure 7 Pea aphid contact assay: Pea aphid survival 24 h after contact exposure to controls (water + 0.01% Breakthru [BT], or Hv1a or GNA / Hv1a (kq), or Hv1a / GNA). All protein treatments contained Breakthru. Bar graphs depict standard error of the mean (9-12 replicates per dose, n=15). Nine to twelve biological replicates (15 aphids / replicate) were performed for each protein treatment and dose; survival was recorded 24 h after treatment.
[0080] Figure 8 .Schematic representation of expression constructs: Schematic constructs encoding recombinant PAF and PAF / GNA. (a) Schematic representation of constructs encoding recombinant PAF and PAF / GNA (produced in the yeast Pichia pastoris, predicted molecular weights are shown); the label indicates the presence of a six-residue histidine sequence that enables protein purification by nickel affinity chromatography and immunoblot detection. (b) Gel electrophoresis: Purified proteins separated by SDS-PAGE gel (17.5% acrylamide) (stained for total protein): protein loading (μg) is depicted. The GNA standard is GNA purified from snowdrop bulbs (Sigma-Aldrich, St. Louis, USA). (c) Immunoblotting: Western blot analysis of recombinant proteins using anti-His (loaded with 400 ng protein) and anti-GNA (loaded with 200 ng protein) antibodies. The positions of mass markers run on the same gel are depicted.
[0081] Fig. 9.Survival of pea aphids 24 h after contact exposure to water, water + Breakthru (BT), ovalbumin, GNA, PAF, PAF / GNA, or a mixture of GNA and PAF. All protein treatments contained BT. Bar graphs depict standard error of the mean (3 replicates per dose, n=15), * indicates significant difference relative to control (+BT) and ovalbumin treatment at **P<0.005 and ***P<0.0005 (t-test).
[0082] Fig.10 .(a) LC-MS data obtained from ProAlanase and Chymotrypsin digests of PAF and PAF / GNA protein products. The light grey horizontal bars depict the identified peptides. Primary structure of the recombinant protein expressed by transformed Pichia cells. Due to incomplete processing of the alpha factor sequence by yeast dipeptidyl aminopeptidase, additional residues EAEAAA remain in the expression product, while the additional alanine is a result of gene insertion via the Pst I restriction site. The remaining residues are a result of the cloning process of the expression construct. (b) Examples of LC-MS spectra obtained after fragmentation of the PAF and PAF / GNA proteins.
[0083] method
[0084] Material
[0085] The Pichia codon-optimized nucleotide sequence encoding ω / κ-hexatoxin-Hv1h (accession number S0F209; residues 38-76) (hereinafter referred to as HxTx-Hv1h) and cloning primers were purchased from Integrated DNA Technologies (IDT). The Pichia codon-optimized nucleotide sequence encoding PA1 without a signal peptide (NCBI accession number P62930, residues 33-103) ( https: / / eu.idtdna.com / CodonOpt ) (hereinafter referred to as PAF) and cloning primers were purchased from Integrated DNA Technologies (IDT). Restriction endonucleases were provided by Thermo Scientific or New England BioLabs. The electrophoresed DNA fragments were purified from the excised gel slices using the Qiagen gel extraction kit. Plasmid DNA was prepared using the Promega Wizard miniprep kit. The T4 ligase kit was provided by Promega. Phusion polymerase was from New England Biolabs. Pichia pastoris (SMD1168H strain), expression vector pGAPZαB and Easycomp Pichia transformation kit were from Invitrogen.
[0086] Anti-GNA antibody was produced by Genosys Biotechnologies, Cambridge, UK. Monoclonal 6x-His tag antibody was from Fisher Scientific, UK. IgG horseradish peroxidase secondary antibody was from Biorad. Chemicals used for chemiluminescence and buffer salts were provided by Sigma.
[0087] Assembly of HxTx-Hv1h and HxTx-Hv1h / GNA fusion protein expression constructs
[0088] The HxTx-Hv1h coding sequence was amplified by PCR using primers containing PstI and SalI restriction sites. After gel purification, the PCR product was digested (PstI and SalI) and ligated into similarly cut vector pGAPZαB DNA. To generate a fusion protein construct in which HxTx-Hv1h was linked to the N-terminus of GNA, the toxin coding sequence ( Figure 1 a) Amplified by PCR (using primers containing PstI and SalI restriction sites), gel purified, restricted, and ligated into the previously generated pGAPZαB construct containing the GNA coding sequence. The plasmid was cloned into electrocompetent E. coli (DH5α) cells and the DNA coding sequence was verified by "in house" DNA sequencing.
[0089] Assembly of PAF and PAF / GNA fusion protein expression constructs
[0090] The PAF coding sequence was amplified by PCR using primers containing PstI and SalI restriction sites. After gel purification, the PCR product was digested (PstI and SalI) and ligated into similarly cut vector pGAPZαB DNA. To generate a fusion protein construct in which PAF was linked to the N-terminus of GNA, the toxin coding sequence ( Figure 8 a) Amplified by PCR (using primers containing PstI and SalI restriction sites), gel purified, restriction enzyme treated, and ligated into the previously generated pGAPZαB construct containing the GNA coding sequence. The plasmid was cloned into electrocompetent E. coli (DH5α) cells and the DNA coding sequence was verified by "in-house" DNA sequencing and analyzed using Serial Cloner 2.6.
[0091] Yeast transformation, expression and purification of recombinant proteins
[0092] According to the manufacturer's instructions, DNA from sequence-verified clones was linearized with AvrII and transformed into chemically competent Pichia cells. Transformants were selected on a medium containing 100 μg / mL zeocin. Western blot analysis (using anti-His or anti-GNA antibodies) of the supernatant of 10 mL cultures grown at 30°C for 2-3 days in YPG medium (1% [w / v] yeast extract, 2% [w / v] peptone, 4% [v / v] glycerol, 100 ug / mL zeocin) was performed, and clones expressing recombinant HxTx-Hv1h or HxTx-Hv1h / GNA or PAF or PAF / GNA were selected to be produced by benchtop fermentation (results not shown).
[0093] For protein production, Pichia cells expressing HxTx-Hv1h or HxTx-Hv1h / GNA or GNA or PAF or PAF / GNA were grown in a benchtop fermenter (ez-control Applikon 7.5L container) as previously described (Fitches et al., 2012). After fermentation, proteins were isolated from cells by centrifugation (20 min, at 7000 g, 4 ° C) and purified via nickel affinity chromatography (as previously described in the art). Pooled fractions containing purified protein were dialyzed against distilled water and lyophilized. Protein content in lyophilized samples was determined from SDS-PAGE gels stained with Coomassie Brilliant Blue for total protein. Quantification was based on the bands corresponding to intact proteins, which were compared to GNA (Sigma) standards by visual inspection, and iBright analysis of gel images was scanned using a commercial flatbed scanner.
[0094] Electrophoresis, Western blotting, and fluorescein conjugation
[0095] SDS-PAGE electrophoresis, Western blotting and fluorescein isothiocyanate (FITC) labeling of recombinant proteins were performed as described previously ( Fitches et al., 2012 ).
[0096] Recombinant protein characterization
[0097] Recombinant HxTx-Hv1h and HxTx-Hv1h / GNA were separated by SDS-PAGE and bands cut from gels stained with Coomassie Brilliant Blue were analyzed by LC-MS. Recombinant PAF and PAF / GNA were separated by SDS-PAGE and bands cut from gels stained with Coomassie Brilliant Blue were analyzed by LC-MS. Proteins in the cut bands were digested with chymotrypsin or ProAlanase and / or trypsin and analyzed by LC-MS using a Sciex TripleTOF 6600 mass spectrometer coupled to an ekspert™ nanoLC 425 (Eksigent) with a low micro gradient flow module via a DuoSpray source (Sciex) (as previously described in the art).
[0098] Insect farming
[0099] Acyrthosiphon pisum (pea aphid) and Myzus persicae (peach-potato aphid) were reared on Vicia faba and Brassica rapa, respectively, and both colonies were maintained at 22°C under a 16h light:8h dark cycle.
[0100] Aphid feeding and choice assay
[0101] Oral toxicity of pea aphid and peach aphid was determined using a cylindrical feeding chamber covered with paraffin film sandwich (containing protein dissolved in liquid artificial diet) (Prosser & Douglas, 1992). A reserve protein solution in sodium phosphate buffer (50mM pH 7.4; SPB) was added to the sterile diet so that 100 μL of diet contained 25 μL of protein solution. The control diet contained an equivalent volume of SPB to the protein treatment. One-day-old nymphs selected from adults maintained on the artificial diet for 24 h were placed on 25 μL of artificial diet (15 nymphs / dose). The diet was changed every 2 days, and survival was recorded every day. Preliminary determinations made it possible to determine the appropriate range of protein concentrations, thereby deriving the median lethal concentration.
[0102] The choice assay was performed similarly to the oral toxicity bioassay, except that 25 μL of the diet containing 0.6 mg / mL of a given test protein was placed between two layers of parafilm on the feeding chamber along with 25 μL of the control diet so that the diets would not mix. Ovalbumin was used as a control protein treatment. Twenty day 1 nymphs were placed between the two diets (3 replicates / choice test), and the number of aphids fed each diet was recorded after 24 h and 48 h.
[0103] Aphid (A. pisum) local assay
[0104] A topical protein delivery method was developed based on the procedure described by Niu et al. (2019), except that adult pea aphids were temporarily immobilized using CO2 and the protein was resuspended in water containing 0.1% (v / v) Breakthru. Anesthetized aphids were individually placed in abdominal contact with a 0.5 μL droplet of protein solution, left for 12 min, and then placed in a feeding chamber. Unlike Nui et al. (2019), the droplet did not completely dry and therefore not all of the protein was adsorbed to the aphid cuticle. Preliminary experiments determined the appropriate protein concentration and appropriate adjuvant. Three to 12 biological replicates (15 aphids / replicate) were performed for each protein treatment and dose; survival was recorded 24 h after treatment. Protein analysis was performed on protein extracts of whole aphids that had been topically treated and then fed a control diet for 2 h and 18 h as follows; aphids (10 / sample) were washed with 20% EtOH, ground with a micro pestle in the presence of 100 μL 5× SDS-sample buffer (containing 10% [v / v] β-mercaptoethanol), boiled for 10 min, and centrifuged, and then 30 μL / lane was loaded on the gel.
[0105] Fluorescence microscopy
[0106] Pea aphids were fed with FITC-labeled proteins (HxTx-Hv1h 0.25mg / mL, GNA 0.75mg / mL, HxTx-Hv1h / GNA1mg / mL) in the diet for 24h and then transferred to a control diet for a 24h chase period. The control was fed a diet containing FITC and 0.1mg / mL propidium iodide (PI) to enable visualization of the intestine. A subgroup of aphids fed with labeled proteins (6 / treatment) were retained as individuals in the feeding chamber to allow newborn nymphs to be visualized. For contact assays, aphids were "immersed" in a labeled protein solution (as previously described) and placed on a control diet for up to 18h. Prior to visualization, aphids were washed by immersion in 20% EtOH to remove unpenetrated protein. Aphids (9-12 per treatment and time point) were visualized using a fluorescence microscope (Leica MC165) under a FITC filter (absorption 494 nm; emission 521 nm), and images were captured in OpenLab. Example
[0107] Recombinant protein production in the yeast Pichia pastoris
[0108] The synthetic genes encoding HxTx-Hv1h and HxTx-Hv1h / GNA were cloned in frame with yeast α-factor in the expression vector pGAPZαB by PCR amplification followed by restriction enzyme treatment and ligation. Figure 1 As depicted in a, fusion proteins are generated by fusing the HxTx-Hv1h protein to the N-terminus of GNA via an 8 amino acid residue (GGGGSAAA) linker region. Both constructs contain a six-residue histidine tag at the C-terminus to enable affinity purification, as well as two additional N-terminal residues, glycine and serine (GS), which are reported to enhance the expression level of HxTx-Hv1h in the yeast Pichia pastoris (WO 2013 / 134734A2). The constructs are cloned into Escherichia coli (E. coli), and the sequenced plasmid DNA is linearized and transformed into competent Pichia pastoris cells. Selection of clones for benchtop fermentation can be achieved by small-scale screening of protein blotting (for protein expression) to produce sufficient amounts of protein for insect bioassays. Pichia pastoris cells are grown in laboratory fermenters, and all recombinant proteins are expressed at levels exceeding 30 mg / L in the culture supernatant. Proteins are purified from clarified supernatants by nickel affinity chromatography, followed by dialysis and freeze drying.
[0109] like Figure 1 As shown in b, the purified recombinant HxTx-Hv1h was separated into two protein products of approximately 17 kDa (more than twice the predicted mass of 7 kDa) on SDS-PAGE gel. Immunoreactivity with anti-His antibody ( Figure 1 c) provides evidence that both proteins represent recombinant toxins, and LC-MS analysis further confirms that both proteins are full-length and have identical sequences. The higher than predicted mass of the recombinant HxTx-Hv1h protein product is believed to be due, at least in part, to the hyperglycosylation commonly observed during recombinant protein expression in Pichia pastoris. The purified HxTx-Hv1h / GNA stained on an SDS-PAGE gel as a single protein of approximately 20 kDa (2 kDa higher than its predicted molecular weight; Figure 1 b), and reacted positively with anti-GNA and anti-His antibodies ( Figure 1 c). LC-MS analysis confirmed the presence of the full-length sequence and that both proteins contained an additional alanine as a result of gene insertion via the PstI restriction site in the pGAPZαB vector. Recombinant GNA containing a C-terminal histidine tag ran on an SDS-PAGE gel at approximately 14 kDa (close to its predicted molecular weight of 12.8 kDa) ( Figure 1 b) The functionality of the GNA component of the recombinant fusion protein was confirmed by in vitro agglutination assay (results not shown).
[0110] The synthetic genes encoding PAF and PAF / GNA were cloned in frame with yeast α-factor in the expression vector pGAPZαB by PCR amplification followed by restriction enzyme treatment and ligation. Figure 8 As shown in a, fusion protein is generated by fusing the full-length PAF protein to the N-terminus of GNA via a 3 amino acid residue (Ala-Ala-Ala) linker region. Both constructs contain a six-residue histidine tag at the C-terminus to enable immunoblotting detection and affinity purification. The construct is cloned into Escherichia coli, and the plasmid DNA sequenced is linearized and transformed into competent Pichia cells. The selection of clones for tabletop fermentation can be achieved by small-scale screening of protein blotting (for protein expression) to produce enough protein for insect bioassays. Pichia cells are grown in laboratory fermenters, and the recombinant protein is purified from clarified supernatant by nickel affinity chromatography, followed by dialysis and freeze drying. PAF and PAF / GNA are expressed at corresponding levels of approximately 40 mg / L and 80 mg / L culture supernatant.
[0111] like Figure 8 As shown in b, the purified recombinant PAF was separated into two protein products of approximately 14 kDa (which is close to the predicted mass of 12.7 kDa) on SDS-PAGE gel. Immunoreactivity with anti-His antibody ( Figure 8 c) provides evidence that both proteins represent recombinant PAF. Staining of PAF by periodic acid Schiff blot analysis confirmed glycosylation of recombinant PAF (but not PAF / GNA), and thus differential glycosylation may be responsible for the presence of two protein products (results not shown). LC-MS analysis of PAF confirmed that both proteins are full-length, composed of both PAlb and PAla peptides, have identical sequences, and contain an additional 5 N-terminal residues (Glu-Ala-Glu-Ala-Ala) due to incomplete processing of the alpha factor sequence by yeast dipeptidyl aminopeptidase, and an additional alanine ( Fig.10 Purified PAF / GNA was separated on SDS-PAGE gel as a single protein of approximately 25 kDa (similar to the predicted mass of 24.5 kDa) ( Figure 1 Both proteins reacted positively with anti-GNA and anti-His antibodies, indicating that the 25 kDa product is intact PAF / GNA, while the minor 14 kDa protein is cleaved GNA ( Figure 1c). LC-MS analysis of the 25 kDa protein confirmed the presence of the full-length sequence and, as with PAF, the presence of additional N-terminal residues (Online Resource 1). As previously reported, recombinant GNA containing a C-terminal histidine tag ran on an SDS-PAGE gel at approximately 14 kDa (close to its predicted molecular weight of 12.8 kDa) ( Figure 8 b, c) (Powell et al., 2019). The functionality of the GNA component of recombinant PAF / GNA was confirmed by in vitro agglutination assay (results not shown).
[0112] Biological activity of recombinant proteins
[0113] Oral toxicity of recombinant proteins to aphids
[0114] Oral toxicity was determined by feeding pea aphid or peach aphid nymphs with an artificial diet containing a range of concentrations (0.2-2 mg / mL) of recombinant HxTx-Hv1h, HxTx-Hv1h / GNA, or GNA. Figure 2 As shown, a dose-dependent decrease in the survival of aphids fed a diet containing protein was observed in all assays, while the survival of the control (diet without added protein) was >85%. HxTx-Hv1h alone was similarly toxic to both species, with 100% mortality observed after 4 days of feeding a diet containing >0.6 mg / ml protein, and comparable LC values of 0.70 mg / mL and 0.68 mg / mL were obtained for pea and peach potato aphids, respectively. 50 The HxTx-Hv1h / GNA fusion protein also showed comparable toxicity to both species, with corresponding LC values of 0.62 mg / mL and 0.59 mg / mL obtained for pea and peach potato aphids. 50 (Day 2) values. Although the LC of HxTx-Hv1h / GNA 50 The values were comparable to the HxTx-Hv1h values based on total protein, but they were approximately 4.5-fold lower based on toxin alone. GNA feeding alone caused a significant decrease in survival of pea aphids at diet concentrations ≥ 0.6 mg / mL (log-rank Mantel-Cox; P < 0.05), whereas no significant differences in survival of peach aphids were observed for any of the GNA treatments compared to control-fed aphids.
[0115] In the choice assay, both aphid species showed a preference for the control (no added protein) diet over each recombinant protein, but no preference was observed for the control diet over the ovalbumin (control non-toxic protein) diet (Online Resource 2). These results suggest that the observed mortality of aphids fed a diet containing protein ( Figure 2 and 3) is at least partly due to the antifeedant effect.
[0116] Further aphid bioassays were performed to verify that the enhanced efficacy of HxTx-Hv1h / GNA was attributable to a direct effect of the fusion protein rather than an additive effect of the combination of feeding toxin and GNA. Figure 3 As shown, 100% mortality of pea aphids or peach aphids was observed after 3 or 4 days, respectively, after feeding a diet containing 0.6 mg / mL of the fusion protein. In contrast, feeding a combination of HxTx-Hv1h (0.15 mg / mL) and GNA (0.45 mg / mL) at equivalent concentrations resulted in 100% mortality of pea aphids and 93% mortality of peach aphids after 5 days of feeding. The survival curves for the fusion protein and combination treatments were significantly different (P=0.0101 pea aphids and P=0.016 peach aphids; Mantel-Cox, log-rank test). Combining the toxin and GNA resulted in an additive effect on aphid survival; for example, after 3 days of feeding, 27% pea aphid mortality and 47% pea aphid mortality were observed for both the HxTx-Hv1h and GNA treatments, respectively (compared to 73% mortality for the treatment containing a mixture of toxin and GNA). The slower onset of complete mortality compared to the no diet control treatment suggests that the mortality was attributable to protein intake rather than simply to food refusal.
[0117] Figure 4 Fluorescence images of whole pea aphid chase feeding control diets after 24 h of feeding with equimolar concentrations of FITC-labeled toxins, fusion proteins or GNA are presented. In aphids fed with control PI, visualization of the foregut is evident. After 24 h of feeding, the labeled protein was easily detectable in aphids, and fluorescence (particularly in the intestinal region) continued for 6 h of the chase feeding period, indicating that all proteins were able to bind to the intestinal epithelium. After 24 h of chase feeding, fluorescence continued in aphids fed with GNA and fusion proteins, but was clearly absent in aphids fed with HxTx-Hv1h, indicating relatively weak binding and faster removal of the toxin. Whole-body fluorescence in adult aphids and fluorescence in the intestinal region of offspring of adults fed with HxTx-Hv1h / GNA indicate that the fusion protein is transported across the aphid intestinal tract to the circulatory system. Although sample sizes were limited (4-5 nymphs / treatment), this was not observed for progeny derived from aphids fed HxTx-Hv1h or GNA, as very few aphids produced nymphs.
[0118] Aphidida pisum
[0119] The efficacy of topically applied proteins was evaluated by exposing pea aphids to drops containing different concentrations of HxTx-Hv1h, HxTx-Hv1h / GNA, or GNA on their abdomens ( Figure 5a). The mean survival of aphids exposed to the water-only control was approximately 80% (compared to 70% and 62%, respectively, for Break-thru (control) or GNA (5 μg) alone), indicating that neither Breakthru nor GNA had a significant effect on aphid survival. In contrast, significant dose-dependent reductions in aphid survival were observed for all HxTx-Hv1h and fusion protein treatments compared to the control (+Break-thru) group. These effects were comparable on a total protein basis; exposure to droplets containing 5.0 μg of HxTx-Hv1h or HxTx-Hv1h / GNA resulted in 89% and 91% reductions in mean survival, while the 1.25 μg treatment reduced aphid survival by 51% and 58%, respectively. When comparing data based on toxin alone (5.0 μg fusion protein consisting of approximately 1.25 μg HxTx-Hv1h and 3.75 μg GNA), 5 μg fusion protein resulted in significantly (P=0.0031; t-test) higher mortality compared to the 1.25 μg HxTx-Hv1h treatment. The survival of aphids exposed to 1.25 μg fusion protein was also lower than that recorded for 0.31 μg HxTx-Hv1h, although this difference was not significant (P=0.101; t-test). In addition, a significant reduction in survival was observed between aphids exposed to droplets containing 5.0 μg fusion protein and a combination of GNA (3.75 μg) and HxTx-Hv1h (1.25 μg) (P=0.013; t-test). These results indicate that fusion with GNA enhances the contact efficacy of HxTx-Hv1h for aphids.
[0120] In additional experiments, protein treatments were calculated on a molar rather than a weight basis to allow for more accurate comparisons of differences in toxicity levels between toxins, fusion proteins, and GNA ( Figure 5b). The average survival of aphids exposed to the water-only control was approximately 80%, compared to 70% for Break-thru alone (BT control) and 62% for GNA (280 pmol). The differences between the water control and BT or GNA were not significant, indicating that neither Breakthru nor GNA had a significant detrimental effect on aphid survival. Exposure to 70 pmol (0.45 μg) of HxTxHv1h did not cause a significant reduction in survival compared to the BT control treatment. In contrast, significant dose-dependent reductions in aphid survival were observed for HxTx-Hv1h (at 280 pmol [1.8 μg] and 800 pmol [5.0 μg]) and fusion protein treatments (70 pmol [1.25 μg] and 280 pmol [5.0 μg]) compared to the BT control group. A significant difference in survival between the fusion protein and toxin-only treatments was observed for both the 70 pmol and 280 pmol treatments (P = 0.0061 and 0.0029, t-test, respectively). In addition, a significant decrease in survival was observed between aphids exposed to droplets containing 280 pmol of the fusion protein or a combination of 280 pmol of GNA (280 pmol = 3.55 μg) and HxTx-Hv1h (280 pmol = 1.8 μg), respectively (P = 0.0158; t-test). These results provide evidence that fusion with GNA significantly enhances the contact efficacy of HxTx-Hv1h against aphids.
[0121] Figure 5 c shows the delivery of proteins across the cuticle after contact exposure to the labeled protein. After being "dipped" in the protein solution, aphids were fed a control diet for 18 h, washed and imaged. There was no fluorescence in control-treated aphids, which contrasts with the whole-body fluorescence observed in aphids treated with GNA, HxTx-Hv1h and fusion proteins, and provides evidence for protein delivery across the cuticle. The intensity of fluorescence appeared generally greater in aphids soaked in fusion proteins and GNA compared to HxTx-Hv1h. Western blot analysis of whole aphid protein extracts prepared at 2 h and 4 h after contact exposure ( Figure 5 d) HxTx-Hv1h was detected but undetectable in samples prepared 18 h after treatment. In contrast, GNA and HxTx-Hv1h / GNA were detected in immunoblot extracts prepared 2 h and 18 h after contact treatment. Although all samples were probed with anti-His antibody, it is possible that the histidine tag was cleaved from HxTx-Hv1h treated aphids, while it remained intact in GNA and fusion protein treated insects.
[0122] Recombinant protein production in the yeast Pichia pastoris (fusion protein containing Hv1a)
[0123] like Figure 6 As shown in b, purified recombinant Hv1a / GNA / His was separated into two protein products on an SDS-PAGE gel as previously described by Powell et al. (2019). Purified His / GNA / Hv1a(kq) was also separated into two protein products of approximately 17 kDa and 18 kDa (similar to the predicted mass of 16.95 kDa); both products have been shown to be intact fusion proteins by LC-MS analysis, and the small difference in mass is believed to be attributable to differences in the degree of glycosylation during expression in Pichia cells. The kq mutation enhances expression of the intact FP, which is described in WO2012 / 131302.
[0124] Local determination
[0125] The efficacy of topically applied proteins was evaluated by exposing pea aphids to drops containing different concentrations of Hv1a, GNA / Hv1a(kq), or Hv1a / GNA on their abdomens ( Figure 7 ). The average survival rate of aphids 24 h after exposure to control treatments (water and Break-thru [BT]) was 76%. For aphids treated with solutions containing the protein, the reduction in survival in the protein treatment was significantly lower compared to the control treatment (t-test; P<0.02). A dose-dependent reduction in survival was observed for Hv1a alone (0.31 μg and 1.25 μg) and the fusion proteins GNA / Hv1a(kq) or Hv1a / GNA (doses of 1.25 μg and 5 μg). Higher mortality was observed for aphids exposed to fusion proteins containing Hv1a (1.25 μg of fusion protein contained 0.31 μg of toxin, and 5.0 μg of fusion protein contained 1.25 μg of toxin) compared to equivalent concentrations of the toxin alone. These differences were significant for 5.0 μg of GNA / Hv1a(kq) and 1.25 μg of Hv1a (t-test: P<0.0001); GNA / Hv1a(kq) 1.25 and 0.31 μg of Hv1a (t-test: P=0.042); 1.25 μg of Hv1a / GNA and 0.31 μg of Hv1a (t-test; P=0.29). We previously demonstrated that treatment with 5 μg of GNA alone (+BT) did not result in a significant decrease in survival compared to control (+BT) treatment ( Figure 5 ). These results indicate that fusion of Hv1a toxin to either end of GNA results in enhanced contact efficacy of Hv1a toxin against aphids.
[0126] The efficacy of topically applied PAF, PAF / GNA was evaluated as described above; ovalbumin was included as a control protein treatment. Fig. 9 As shown, the average survival of aphids after 24h exposure to Break-thru alone (BT control) was over 80%, while it was 75% for the ovalbumin control protein treatment. Survival after exposure to GNA or lower doses of PAF (50 and 200 pmol) was lower than the control treatment, but not significantly. Exposure to the highest PAF concentration (400 pmol) caused a significant decrease in survival compared to the control, as did the combined treatment (200 pmol of GNA and 200 pmol PAF); this suggests that PAF does have contact activity (albeit at high doses) and that the effects of GNA and PAF are additive. In contrast, significant differences in survival were observed for both PAF / GNA treatments (50 and 200 pmol) compared to the control.
[0127] Significant differences between the survival rates of PAF / GNA- and PAF-treated aphids were observed for both the 50 pmol and 200 pmol treatments (P=0.002 and P=0.0023, respectively; t-test), indicating that the fusion protein was significantly more toxic (compared to PAF alone) (P=0.002 and P=0.0023; t-test). In addition, the mortality of aphids exposed to 200 pmol and 50 pmol of the fusion protein was found to be significantly greater than that of aphids treated with 400 pmol of PAF. That the efficacy was enhanced as a result of the fusion of the two components in the recombinant PAF / GNA (rather than the additive effects of the individual components) was demonstrated by the significantly greater mortality of aphids exposed to 200 pmol of PAF / GNA than to an equivalent mixture of 200 pmol of PAF and GNA, respectively (P=0.0029; t-test). These results provide evidence that the fusion of PAF to GNA significantly enhances the contact efficacy of pea albumin protein against pea aphids.
[0128] in conclusion
[0129] The inventors have demonstrated that, in addition to oral activity, neurotoxins derived from recombinant HxTx-Hv1h venom also have contact activity against aphid pests. However, despite being toxic in themselves, the inventors have demonstrated that fusion of HxTx-Hv1h or Hv1a with another protein, such as GNA, enhances contact efficacy against aphids. Similarly, it is proposed that Vestaron -Lep products are used in combination with low doses of BtK (Bacillus thuringiensis var. kurstaki (Bt var. kurstaki) to enhance the delivery of HxTx-Hv1h toxin to the CNS due to the ability of BtK to form pores in the midgut of certain pests. In addition, the inventors have demonstrated that recombinant pea albumin proteins also have contact activity, which is significantly enhanced when fused to GNA. Therefore, fusion protein-based approaches delivered by contact application may provide an alternative route of administration or the opportunity to further enhance the efficacy of toxins such as HxTx-Hv1h or Hv1a, or PAF (pea albumin) to pests, including those that are resistant to the effects of Bt toxins.
[0130] References
[0131] Atkinson RK, Vonarx EJ, Howden MEH (1996) Effects of whole venom and venom fractions from several Australian spiders, including Atrax (Hadronyche) species, when injected into insects. Comp. Biochem. Physiol. 114C, 113±117.
[0132] Bonning BC,Pal N,Li,S,Wang Z,Sivakumar S,Dixon PM,King GF,Miller WA(2014)Toxin delivery by the coat protein of an aphid-vectored plant virusprovides plant resistance to aphids.Nature Biotechnology 32(1):102-105.https: / / doi:10.1038 / nbt.2753.
[0133] Chambers C,Cutler P,Huang Y-H,Goodchild JA,Blythe J,Wang CK,Bigot A,Kaas Q,Craik DJ,Sabbadin D,Earley FG(2019).Insecticidal spider toxins arehigh affinity positive allosteric modulators of the nicotinic acetylcholinereceptor.FEBS Letters 593:1336-1350. https: / / doi : 10.1002 / 1873-3468.13435.
[0134] Chong Y,Hayes JL,Sollod BL,Wen S,Hains PG(2007)The omega-atracotoxins:selective blockers of insect M-LVAand HVA calciumchannels.Biochemical Pharmacology 74:623–638.https: / / 10.1016 / j.bcp.2007.05.017.
[0135] Craik DJ,Daly NL,Waine C(2001)The cystine knot motif in toxins andimplications for drug design.Toxicon 39(1),43–60.https: / / doi. 10.1016 / s0041- 0101(00)00160-4.
[0136] Fletcher JI,Smith R,O’Donoghue SI,Nilges M,Connor M,Howden,ME(1997)The structure of a novel insecticidal neurotoxin,v-atracotoxin-HV1,from thevenom of an Australian funnel web spider.Nature Structural Biology4:559–66.https: / / 10.1038 / nsb0797-559.
[0137] Fitches E,Edwards MG,Mee C,Grishin E,Gatehouse AMR,Edwards JP,Gatehouse JA(2004)Fusion proteins containing insect-specific toxins as pestcontrol agents:snowdrop lectin delivers fused insecticidal spider venom toxinto insect haemolymph following oral ingestion.Journal of Insect Physiology50:61-71.doi:10.1016 / j.jinsphys.2003.09.010.
[0138] Fitches EC,Bell HA,Powell ME,Back E,Sargiotti C,Weaver RJ,GatehouseJA(2010)Insecticidal activity of scorpion toxin(ButaIT)and snowdrop lectin(GNA)containing fusion proteins towards pest species of different orders.PestManag Sci 66(1):74–84.https: / / doi.org / 10.1002 / ps.1833.
[0139] Fitches EC,Pyati PS,King GF,Gatehouse JA(2012)Fusion to snowdroplectin dramatically enhances the oral activity of the insecticidal peptideω-hexatoxin-Hv1a by mediating its delivery to the central nervous system.PloSOne 7:e39389.
[0140] Herzig V,de Araujo AD,Greenwood KP,Chin YK,Windley MJ,Chong Y,Muttenthaler M,Mobli M,Audsley N,Nicholson GM,Alewood PF,King GF(2018)Evaluation of chemical strategies for improving the stability and oraltoxicity of insecticidal peptides.Biomedicines 6:90-105.https: / / doi: 10.3390 / biomedicines6030090.
[0141] King GF,Hardy MC(2013)Spider-venom peptides:Structure,pharmacology,and potential for control of insect pests.Annual Review of Entomology.58:475-496. https: / / doi.org / 10.1146 / annurev-ento-120811-153650.
[0142] Niu J,Yang W-J,Tian Y,Fan J-Y,Ye C,Shang F,Ding B-Y,Zhang J,An X,YangL,Chang T-Y,Christiaens O,Smagghe G,Wang J-J(2019)Topical dsRNA deliveryinduces gene silencing and mortality in the pea aphid.Pest Manag Sci 2019;75:2873–2881.https: / / doi.10.1002 / ps.5457.
[0143] Pallagh PK,Nielsen KJ,Craik DJ,Norton RS(1994)A common structuralmotif incorporating a cystine knot and a triple-strandedβ-sheet in toxic andinhibitory polypeptides.Protein Sci.3,1833–1839(1994).https: / / doi.10.1002 / pro.5560031022
[0144] Pineda SS, Chaumeil PA, Kunert A, Kaas Q, Thang, MWC, Le L, Nuhn M, Herzig V, Saez NJ, Cristofori - Armstrong B, Anangi R, Senff S, Gorse D, King GF (2018) ArachnoServer 3.0: an online resource for automated discovery, analysis and annotation of spider toxins. Bioinformatics 34, 1074–1076.
[0145] Powell, M.E., Bradish, H.M., Cao, M., Makinson, R., Brown, A.P., Gatehouse, J.A. and Fitches, E.C., 2020. Demonstrating the potential of a novel spider venom - based biopesticide for target - specific control of the small hive beetle, a serious pest of the European honeybee. Journal of pest science, 93(1), pp.391 - 402.
[0146] Saez NJ, Herzig V (2019) Versatile spider venom peptides and their medical and agricultural applications. Toxicon, 158:109 - 126. doi:https: / / doi.org / 10.1016 / j.toxicon.2018.11.298.
[0147] Tedford HW,Gilles N,Menez A,Doering CJ,Zamponi GW,King GF(2004)Scanning mutagenesis of v-atracotoxin-Hv1a reveals a spatially restrictedepitope that confers selective activity against insect calciumchannels.Journal of Biological Chemistry 279:44133–40.https: / / doi:10.1074 / jbc.M404006200.
Claims
1. A method for controlling plant pests or bee pests, the method comprising applying to the pests by contact / topical application an insecticide formulation comprising at least one insecticidal recombinant toxin fusion protein or a fragment or variant thereof.
2. The method according to claim 1, which is a method for controlling plant pests.
3. The method according to claim 1, which is a method for controlling bee pests.
4. The method of claim 3, wherein the honey bee pest is a small hive beetle or a parasitic mite.
5. The method according to any one of claims 1 to 4, wherein the at least one insecticidal recombinant toxin fusion protein or a fragment or variant thereof is fused to a carbohydrate binding module.
6. The method according to any one of claims 1 to 5, wherein the at least one insecticidal recombinant toxin fusion protein or a fragment or variant thereof comprises a protein containing an ICK motif or a fragment or variant thereof.
7. The method according to any one of claims 1 to 5, wherein the insecticidal recombinant toxin fusion protein or a fragment or variant thereof comprises a toxin derived from an arachnid or a fragment or variant thereof or a toxin derived from an insect or a fragment or variant thereof.
8. The method of claim 7, wherein the arachnid-derived toxin is a spider toxin or a fragment or variant thereof.
9. The method of claim 8, wherein the spider toxin is hexatoxin.
10. The method of claim 9, wherein the hexatoxin is HxTx-Hv1h, Hv1a, or a variant or fragment thereof.
11. The method of claim 6, wherein the protein containing the ICK motif comprises pea albumin or a fragment or variant thereof.
12. The method according to claim 6, wherein the protein containing the ICK motif comprises PAF or a fragment or variant thereof.
13. The method of any one of claims 5 to 12, wherein the carbohydrate binding module comprises a lectin.
14. The method of claim 13, wherein the lectin comprises a mannose binding lectin.
15. The method of claim 14, wherein the lectin comprises Galanthus galanthus agglutinin (GNA).
16. The method of any preceding claim, wherein the insecticidal recombinant toxin fusion protein further comprises a linker sequence between the toxin protein and the carbohydrate binding module.
17. The method of claim 16, wherein the linker sequence comprises the sequence (G)nS(A)n, (G)n, (GGGGS)n, wherein n is 2 to 6.
18. The method of any one of claims 2-17, wherein the insecticidal recombinant toxin fusion protein or a fragment or variant thereof is fused to the N-terminus or C-terminus of the carbohydrate binding module.
19. The method according to any preceding claim, wherein the insecticidal recombinant toxin fusion protein comprises any one or more proteins selected from SEQ ID NO: 6 to SEQ ID NO:
13.
20. The method according to claim 19, wherein the insecticidal recombinant toxin fusion protein comprises any one or more proteins selected from SEQ ID NO: 7 to SEQ ID NO:
13.
21. The method of any preceding claim, wherein the insecticidal recombinant toxin fusion protein comprises SEQ ID NO:
15.
22. A method according to any preceding claim, wherein the pesticide formulation further comprises one or more excipients, carriers and / or adjuvants.
23. The method of claim 22, wherein the excipients of the pesticide formulation include one or more surfactants.
24. The method of claim 23, wherein the one or more surfactants include non-ionic spreading and penetrating surfactants and / or non-ionic silicone surfactants.
25. The method of claims 22 to 24, wherein the pesticide formulation further comprises a pest attractant and / or a sticky substance for promoting adhesion of the pesticide formulation to the external surface of the pest.
26. A chemical composition comprising the insecticidal recombinant toxin fusion protein according to claims 17 to 21, wherein the recombinant toxin fusion protein is formulated for agricultural use together with one or more excipients, carriers and / or adjuvants.
27. The chemical composition of claim 26, wherein the excipients of the pesticide formulation include one or more surfactants.
28. The chemical composition of claim 27, wherein the one or more surfactants include nonionic spreading and penetrating surfactants and / or nonionic silicone surfactants.
